Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-A9-3202
- Development stage
- Unknown
- Lead developer
- Alpha-9 Oncology
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
68Ga-A9-3202 is a radiodiagnostic imaging agent developed by Alpha-9 Oncology for the detection of locally advanced or metastatic melanoma. It is a gallium-68 labeled compound that targets the melanocortin 1 receptor (MC1R), which is highly expressed in malignant melanoma cells. The agent is designed for use with PET/CT imaging to enhance visualization of tumors and assess their distribution in patients. Its primary mechanism involves acting as a positron-emission tomography (PET) enhancer by binding specifically to MC1R on tumor cells, thereby enabling precise imaging and potentially identifying candidates for targeted radiotherapeutic interventions[1][3][6]. As of May 2024, it has entered Phase I clinical trials in Australia for the diagnosis of malignant melanoma[1][8].
- Other names
- 68Ga-A9T-3202A9-3202A-9-3202A 9-3202
02
Targets
MC1R (Melanocortin Type 1 Receptor)
Beyond the preview
Go deeper on 68Ga-A9-3202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-A9-3202.